Open AccessSurvival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand.
Author(s) -
David C. Parker,
Dale L. Greiner,
Nancy E. Phillips,
Michael C. Appel,
Alan W. Steele,
Fiona H. Durie,
Randolph J. Noelle,
John P. Mordes,
Aldo A. Rossini
Publication year - 1995
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.92.21.9560
Subject(s) - islet , immunology , cd40 , antigen , antibody , transplantation , clonal deletion , histocompatibility , mixed lymphocyte reaction , biology , medicine , cytotoxic t cell , immune system , human leukocyte antigen , t cell , endocrinology , in vitro , insulin , biochemistry , t cell receptor
Combined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.